Epigenomics’ partner BioChain successfully completes clinical validation study in China
Epigenomics and BioChain Institute announced that BioChain has completed its major clinical validation study to validate Epigenomics’ blood-based Septin9 screening assay Epi proColon® for the early detection of colorectal cancer with the goal to gain market approval for the test in China. April 24, 2014